Usefulness of penbutolol for systemic hypertension. Penbutolol Research Group

The American Journal of Cardiology
J A Schoenberger

Abstract

Dose-response relations with penbutolol--a beta-adrenergic blocking agent--were evaluated in a double-blind multiclinic study conducted in 302 outpatients with mild to moderate hypertension (untreated supine diastolic blood pressure [BP] greater than or equal to 95 and less than or equal to 115 mm Hg). Penbutolol was administered once daily in 10, 20 or 40 mg doses for 6 weeks and compared with placebo. Mean declines from baseline in supine diastolic BP were comparable in the 3 penbutolol treatment groups and significantly superior to placebo (p less than 0.05). A significant difference between penbutolol dosage groups was observed only for supine systolic BP; the mean decline at 20 mg/day was significantly larger than that at 10 mg/day (p less than 0.05). Maximum BP response developed in approximately 4 weeks at 10 mg/day and in 2 weeks at the higher dosages. Decline in mean heart rate after 6 weeks of penbutolol therapy significantly exceeded placebo only at 40 mg/day (7.2 vs 2.5 beats/min, p less than 0.05). Treatment was well-tolerated and discontinued because of adverse effects in only 7 patients receiving penbutolol and 3 receiving placebo. The lack of significant bradycardia and the low incidence of other troublesome adv...Continue Reading

References

Apr 1, 1977·Journal of Clinical Pharmacology·J J VallnerI L Honigberg
Apr 1, 1977·British Journal of Clinical Pharmacology·J F GiudicelliA Berdeaux
Jan 1, 1979·European Journal of Clinical Pharmacology·G NybergA Vedin
Jan 1, 1977·The Journal of International Medical Research·V H YajnikS H Patel
Jan 1, 1986·European Journal of Clinical Pharmacology·H SpahnE E Ohnhaus
May 1, 1985·British Journal of Clinical Pharmacology·N D BaxH F Woods
Jan 1, 1985·European Journal of Clinical Pharmacology·N BernardJ Sassard

Citations

May 1, 1990·Journal of Clinical Pharmacology·W H Frishman, S Covey
Mar 4, 2014·The Cochrane Database of Systematic Reviews·Gavin W K Wong, James M Wright
Apr 1, 1990·DICP : the Annals of Pharmacotherapy·K D Schlanz, R L Thomas
Apr 1, 1991·Postgraduate Medicine·A M ReyJ G Gums

Related Concepts

Diastolic Blood Pressure
Double-Blind Method
Drug Administration Schedule
Pulse Rate
Hypertensive Disease
Betapressin
Placebos
Propanolamines
Randomization
Multicenter Trials

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.